Key Financial Results - Q2 FY27 (Standalone)

Operating Income: ₹234.89 crore (up 50.15% YoY from ₹156.43 crore in Q2 FY26)

Operating EBITDA: ₹42.33 crore (up 4.95x YoY from ₹8.55 crore)

Operating EBITDA Margin: 18.02% (expanded by 1,256 basis points from 5.46%)

PAT: ₹31.03 crore (up 3.54x YoY from ₹8.76 crore)

PAT Margin: 13.21% (expanded by 761 basis points from 5.60%)

PBT: ₹40.24 crore (up 3.6x YoY)

Finance Cost: ₹1.33 crore (declined 33.83% YoY)

Other Income: ₹7.60 crore (declined 35.95% YoY)

Raw Material Expense: 45.15% of revenue (improved 423 basis points from 49.38% in Q2 FY26)

Key Financial Results - H1 FY27 (Standalone)

Operating Income: ₹420.97 crore (up 35.79% YoY from ₹310.02 crore)

Operating EBITDA: ₹75.65 crore (up 4.45x YoY from ₹16.98 crore)

Operating EBITDA Margin: 17.97% (expanded by 1,253.66 basis points from 5.47%)

PAT: ₹55.47 crore (up 3.29x YoY from ₹16.88 crore)

PAT Margin: 13.18% (expanded by 773.35 basis points from 5.44%)

Sequential Performance

Q2 vs Q1 FY27: Revenue grew 26.23% from ₹186.08 crore, Operating EBITDA grew 27.02% from ₹33.32 crore, with Operating EBITDA margin improving from 17.91% to 18.02%.

Management Commentary

Mr. N.R. Munjal, Chairman, stated that Q2 performance validates the company's strategic transition from API manufacturer to Finished Dosage Formulations (FDF) manufacturer. The scale-up of operations has improved business mix and lifted margins, with operating leverage delivering improved profitability. The company maintains a net-debt-free balance sheet and remains committed to scaling operations further and sustaining profitable growth.

Business Context

Company has transitioned to a pure-play formulations platform with presence across 85+ countries. CDMO partnerships have started contributing better to topline. The company operates manufacturing facilities with multiple international regulatory accreditations and has dedicated formulation R&D infrastructure.

Capital Structure

Company maintains a net-debt-free balance sheet following strategic restructuring and API & CRAMS divestment.

Forward-looking Statements

Document contains forward-looking statements subject to risks including government actions, local developments, and technological risks. Company does not commit to publicly updating these statements.